Form 4: CompuGen Ltd. Executive Trades Ordinary Shares

Zurit Levine, SVP of Business Development at CompuGen Ltd., reports transactions involving ordinary shares and stock options under a Rule 10b5-1 trading plan.

Summary

• Zurit Levine, Senior Vice President of Business Development at CompuGen Ltd., has reported several transactions related to the company's ordinary shares and stock options.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 23, 2025.
• Specifically, 2,500 ordinary shares were acquired at $0.8292 per share, and 1,000 ordinary shares were acquired at $1.15 per share.
• Additionally, 3,500 ordinary shares were disposed of at $2.20 per share.
• The filing also details the acquisition of stock options: 2,500 options with an exercise price of $0.8292 and 1,000 options with an exercise price of $1.15.
• Vesting schedules for these options are outlined, contingent on continued service to the Issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports routine executive stock transactions under a pre-established plan, with both acquisitions and disposals, indicating a balanced approach rather than a strong directional signal.

Positives

• The executive's acquisition of ordinary shares at lower price points ($0.8292 and $1.15) could indicate a belief in future price appreciation.
• The adoption of a Rule 10b5-1 trading plan demonstrates a structured and pre-planned approach to stock transactions, often viewed positively for its adherence to compliance and avoidance of insider trading perceptions.

Negatives

• The disposal of 3,500 ordinary shares at a higher price ($2.20) suggests a profit-taking action by the reporting person.

Risks

• The continued service requirement for option vesting implies that job security or continued employment with CompuGen Ltd. is a factor in the executive's equity compensation.
• The Rule 10b5-1 plan, while structured, is subject to market fluctuations and the company's performance, which could impact the value of future transactions.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding future financial performance. However, the acquisition of shares and options under a Rule 10b5-1 plan suggests a structured approach to managing executive equity, which may imply confidence in the company's future prospects.

Management Comments

• The transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025.
• Option vesting is subject to the Reporting Person's continued service to the Issuer.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing executive stock option grants and share transactions are common within the biotechnology and technology sectors, where CompuGen Ltd. operates. The use of Rule 10b5-1 plans is a standard practice for executives to diversify holdings or manage personal finances while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders: The transactions may provide insight into executive confidence, but the Rule 10b5-1 plan limits immediate interpretability as a direct market signal.
• Employees: The vesting of options for the SVP of Business Development is tied to continued employment, reinforcing the importance of employee retention and performance.
• Management: The filing confirms adherence to regulatory requirements for reporting beneficial ownership changes.

Next Steps

• Continued vesting of stock options based on continued service.
• Potential future transactions under the Rule 10b5-1 trading plan.

Key Dates

Keywords

CompuGen Ltd., CGEN, Form 4, Stock Options, Ordinary Shares, Beneficial Ownership, Rule 10b5-1, Insider Trading, Executive Transactions, SEC Filing